Skip to main content
TECH
NASDAQ Life Sciences

Bio-Techne Files Definitive Proxy Materials for $73/Share Acquisition by Merck KGaA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$70.94
Mkt Cap
$11.069B
52W Low
$43.195
52W High
$72.16
52W Position info
64% above low
Off High info
1.7% below high
Rel. Volume info
15× avg
Market data snapshot near publication time

TECH sits 64% above its 52-week low of $43.195 on elevated volume (15× avg).

Summary

Bio-Techne has filed definitive additional proxy materials, formally communicating its definitive agreement to be acquired by Merck KGaA for $73.00 per share in cash, a premium to its current trading price and 52-week high.


Key Events · M&A and Partnerships · TECH

  • Definitive Acquisition Agreement

    Bio-Techne has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, for $73.00 per share in an all-cash transaction.

  • Premium Offer

    The $73.00 per share offer represents a premium to the current stock price of $70.94 and the 52-week high of $72.16.

  • Shareholder Approval Required

    The transaction is subject to customary closing conditions, including approval by Bio-Techne shareholders and receipt of required regulatory approvals.

  • Employee Equity Treatment Detailed

    The filing outlines how stock options, RSUs, PSUs, and restricted stock awards will be converted into cash payments based on the $73.00 per share acquisition price.


Analysis · TECH · Life Sciences

This DEFA14A filing provides the formal communications to employees, customers, and partners regarding the definitive agreement for Bio-Techne to be acquired by Merck KGaA for $73.00 per share in cash. This acquisition, priced at a premium to the current stock price and 52-week high, represents a significant positive outcome for shareholders. The filing also details the treatment of employee equity awards and outlines the timeline and conditions for closing, including the need for shareholder and regulatory approvals. This is a critical step in the M&A process, moving the company towards a definitive change of ownership.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 51.2% of the 201 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.73%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TECH was trading at $70.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.1B. The 52-week trading range was $43.20 to $72.16. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TECH - Latest Insights

TECH
Sep 23, 2026, 5:08 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $72.52
Real-time Price: $72.78 info
Change: +$0.260 (+0.36%) info
Market Cap: $11.431B info
TECH
Sep 23, 2026, 9:20 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $72.55
Real-time Price: $72.78 info
Change: +$0.230 (+0.32%) info
Market Cap: $11.431B info
TECH
Sep 14, 2026, 4:47 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $72.29
Real-time Price: $72.78 info
Change: +$0.490 (+0.68%) info
Market Cap: $11.431B info
TECH
Sep 14, 2026, 4:46 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $72.29
Real-time Price: $72.78 info
Change: +$0.490 (+0.68%) info
Market Cap: $11.431B info
TECH
Aug 24, 2026, 4:31 PM EDT
Filing Type: 10-K
Importance Score:
7
Price at Filing: $72.33
Real-time Price: $72.78 info
Change: +$0.450 (+0.62%) info
Market Cap: $11.431B info